Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter--still a dilemma?

Neuro Oncol. 2015 Nov;17(11):1425-7. doi: 10.1093/neuonc/nov198. Epub 2015 Sep 15.

Authors

Monika E Hegi¹, Roger Stupp¹

Affiliation

¹ Neuroscience Research Center, and Service of Neurosurgery, Lausanne University Hospital, Lausanne (CHUV) (M.E.H); Department of Oncology, University Hospital Zurich, Zurich, Switzerland (R.S).

No abstract available

Publication types

Editorial

MeSH terms

Antineoplastic Agents / therapeutic use*
Brain Neoplasms / drug therapy*
Brain Neoplasms / genetics
DNA Methylation / genetics
DNA Modification Methylases / genetics*
DNA Repair Enzymes / genetics*
Dacarbazine / analogs & derivatives*
Dacarbazine / therapeutic use
Glioblastoma / drug therapy*
Glioblastoma / genetics
Humans
Promoter Regions, Genetic / genetics
Temozolomide
Tumor Suppressor Proteins / genetics*

Substances

Antineoplastic Agents
Tumor Suppressor Proteins
Dacarbazine
DNA Modification Methylases
MGMT protein, human
DNA Repair Enzymes
Temozolomide